Objective

CAR-T cell therapy has revolutionized the treatment of oncological diseases, and potential uses in autoimmune diseases have recently been described. The review aims to integrate the available data on treatment with CAR-T cells, emphasizing autoimmune diseases, to determine therapeutic advances and their possible future clinical applicability in autoimmunity.

Materials and methods

A search was performed in PubMed with the keywords “Chimeric Antigen Receptor” and “CART cell”. The documents of interest were selected, and a critical review of the information was carried out.

Results

In the treatment of autoimmune diseases, in preclinical models, three different cellular strategies have been used, which include Chimeric antigen receptor T cells, Chimeric autoantibody receptor T cells, and Chimeric antigen receptor in regulatory T lymphocytes. All three types of therapy have been effective. The potential adverse effects within them, cytokine release syndrome, cellular toxicity and neurotoxicity must always be kept in mind.

Conclusions

Although information in humans is not yet available, preclinical models of CAR-T cells in the treatment of autoimmune diseases show promising results, so that in the future, they may become a useful and effective therapy in the treatment of these pathologies.

中文翻译：

---

嵌合抗原受体 T 细胞（CAR-T 细胞）是自身免疫疾病免疫疗法的未来吗？

客观的

CAR-T 细胞疗法彻底改变了肿瘤疾病的治疗，并且最近描述了自身免疫疾病的潜在用途。该审查旨在整合有关 CAR-T 细胞治疗的可用数据，强调自身免疫性疾病，以确定治疗进展及其未来可能在自身免疫中的临床适用性。

材料和方法

在 PubMed 中使用关键字“嵌合抗原受体”和“CART 细胞”进行搜索。选择了感兴趣的文件，并对信息进行了严格审查。

结果

在自身免疫性疾病的治疗中，在临床前模型中，使用了三种不同的细胞策略，包括嵌合抗原受体 T 细胞、嵌合自身抗体受体 T 细胞和调节性 T 淋巴细胞中的嵌合抗原受体。这三种疗法都有效。必须始终牢记其中的潜在副作用、细胞因子释放综合征、细胞毒性和神经毒性。

结论

虽然目前还没有关于人类的信息，但 CAR-T 细胞治疗自身免疫性疾病的临床前模型显示出有希望的结果，因此在未来，它们可能成为治疗这些病理的有用且有效的疗法。